Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 166

Results For "IND"

7259 News Found

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
News | February 09, 2026

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26


DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies
News | February 09, 2026

DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies

Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments


Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
Drug Approval | February 07, 2026

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets


Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke
Clinical Trials | February 07, 2026

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke


Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease
Drug Approval | February 07, 2026

Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease

This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease


Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients
Drug Approval | February 07, 2026

Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors


£1bn London Cancer Hub expansion wins planning approval
R&D | February 07, 2026

£1bn London Cancer Hub expansion wins planning approval

The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site


Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening
News | February 07, 2026

Hologic’s Aptima HPV test bags FDA nod for primary cervical cancer screening

Hologic has been at the forefront of cervical cancer screening for decades


Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls
News | February 06, 2026

Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls

Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children